Ministry of health, Istanbul Training and Research Hospital, Department of General Surgery - Istanbul, Turkey.
Ministry of health, Istanbul Training and Research Hospital, Department of Medical Pathology - Istanbul, Turkey.
Rev Assoc Med Bras (1992). 2022 Jan;68(1):94-99. doi: 10.1590/1806-9282.20210865.
Our aim was to investigate the hemogram index parameters and their clinical significance in the evaluation of the inflammatory response of patients with male breast cancer, who are rarely observed in the literature.
In total, 22 (n=22) healthy male and 28 (n=28) male breast cancer patients without synchronous/metachronous tumors were included in this study. They were grouped as the healthy male control group (Group 1) and the male breast cancer patient group (Group 2). The male breast cancer was divided into two subgroups, namely, early stage [(stage: 0/I/II) (Group 2A)] and late stage [(stage: III/IV) (Group 2B)], and their hemogram index parameters were compared.
A significant (p>0.05) increase was observed in neutrophil/lymphocyte ratio (NLR) and·platelet/lymphocyte ratio (PLR) values in the late stage (Group 2B: stage III/IV) compared to the early stage (Group 2A: stage 0/I/II) and healthy control (Group 1) groups.
In male breast cancer patients, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio values were significantly higher as the stage of cancer increased. These readily available simple tests can be used to evaluate the host's inflammatory response in male breast cancer.
我们旨在研究男性乳腺癌患者炎症反应评估中的血液学指标参数及其临床意义,因为此类患者在文献中很少被观察到。
本研究共纳入 22 名(n=22)健康男性和 28 名(n=28)无同步/异时性肿瘤的男性乳腺癌患者。他们被分为健康男性对照组(第 1 组)和男性乳腺癌患者组(第 2 组)。男性乳腺癌分为两个亚组,即早期(分期:0/I/II)(第 2A 组)和晚期(分期:III/IV)(第 2B 组),并比较其血液学指标参数。
晚期(第 2B 组:III/IV 期)与早期(第 2A 组:0/I/II 期)和健康对照组(第 1 组)相比,中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)值显著升高(p>0.05)。
在男性乳腺癌患者中,随着癌症分期的增加,中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值显著升高。这些易于获得的简单检测可以用于评估男性乳腺癌患者的宿主炎症反应。